Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

Real-world data on guselkumab, especially at times >6 months, are limited. We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

目前关于古塞奇尤单抗（guselkumab）的真实世界数据较为有限，尤其是用药时长超过6个月的相关研究数据。本研究针对307例中度至重度慢性斑块状银屑病患者（银屑病面积与严重性指数[Psoriasis Area Severity Index, PASI]＞10）开展了一项纵向回顾性分析，所有患者均接受古塞奇尤单抗治疗，最长随访时点达52周（约12个月）。分别于基线及第4、12、20、28、36、44、52周评估患者的PASI 75、PASI 90及PASI 100应答情况。用药12周时，分别有56.4%、33.6%及24.1%的患者达到PASI 75、PASI 90及PASI 100应答标准；至52周时，上述应答率分别升至82.7%、68.7%及51.1%。无合并症且既往未接受过生物治疗的患者，其治疗应答效果更佳。患者的皮肤病生活质量指数（Dermatology Life Quality Index）平均评分从基线时的14.0降至12周时的3.1及6个月时的1.6，且该改善情况在后续随访时点得以维持。瘙痒视觉模拟评分（pruritus visual analog scale）也呈现出相似的改善趋势。在本项中度至重度斑块状银屑病患者的真实世界队列中，古塞奇尤单抗对治疗应答者的疗效可维持至12个月，这一结果验证了既往小型队列及随访时长更短的真实世界研究数据。